Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04844606 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
A Phase 3 study of Ulcerative Colitis and Crohn's Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT04844606: Recruiting Phase 3 study of Ulcerative Colitis and Crohn's Disease, sponsored by Eli Lilly and Company.
NCT04844606 is a Phase 3 study of Ulcerative Colitis and Crohn's Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04844606, a Phase 3 study of Ulcerative Colitis and Crohn's Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.
Primary Outcome
Clinical Remission based on the MMS
Conditions Studied
Interventions
- DRUG Mirikizumab
Study Locations (20)
Other
- Medizinische Universität Wien - Vienna
- UZ Brussel - Brussels
- Cliniques universitaires Saint-Luc - Brussels
- Antwerp University Hospital - Edegem
- UZ Gent - Ghent
- UZ Leuven - Leuven
- Centro de Pesquisa Sao Lucas - Campinas
- Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância - Curitiba
- Universidade Federal de Goias - Goiânia
- Hospital de Clinicas de Porto Alegre - Porto Alegre
Georgia
- Emory University School of Medicine - Atlanta
- Children's Center for Digestive Health Care, LLC - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
- Massachusetts General Hospital - Waltham
California
- UCSF Medical Center at Mission Bay - San Francisco
Connecticut
- Connecticut Children's Medical Center - Hartford
Missouri
- Washington University School of Medicine - St Louis
New York
- Icahn School of Medicine at Mount Sinai - New York
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What NCT04844606 shows while recruiting
NCT04844606 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Mirikizumab is the first listed.
NCT04844606 names 20 study sites across 9 states, led by Other, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04844606 about?
NCT04844606 is a clinical study titled "A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)". The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continu...
What is the current status of trial NCT04844606?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2021-05-26. Estimated completion is 2030-12.
What conditions does trial NCT04844606 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Diseases, Ulcerative Colitis Chronic.
What interventions are being tested in trial NCT04844606?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT04844606?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04844606 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04844606's enrollment target sits among peer trials
150 50th of 122 higher than 73 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI